Details of the Drug Combination

General Information of Drug Combination (ID: DCGS3LR)

• Drug Combination Name: TG100-115 + Pyronaridine
• Indication: Hepatoblastoma; Status: Investigative [1]
• Component Drugs:
  TG100-115 (DMON4IL): Small molecular drug
  Pyronaridine (DMUWAM2): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: HB3
  Zero Interaction Potency (ZIP) Score: 0.044
  Bliss Independence Score: 0.098
  Loewe Additivity Score: 0.051
  LHighest Single Agent (HSA) Score: 0.098

Molecular Interaction Atlas of This Drug Combination

Indication(s) of TG100-115

Disease Entry	ICD 11	Status	REF
Angioedema	4A00.15	Phase 1/2	[2]
Myocardial infarction	BA41-BA43	Phase 1/2	[2]

TG100-115 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
PI3-kinase gamma (PIK3CG)	TTHBTOP	PK3CG_HUMAN	Inhibitor	[4]

Indication(s) of Pyronaridine

Disease Entry	ICD 11	Status	REF
Malaria	1F40-1F45	Approved	[3]

Pyronaridine Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A)	TTZVSJ2	NOUNIPROTAC	Inhibitor	[5]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5715).
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic can... J Pharmacol Exp Ther. 2009 Mar;328(3):758-65.
• [5] The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.